International Journal of Computer Information Systems and Industrial Management Applications
ISSN 2150-7988 Volume 18(7s) 2026 pp. 1226-1239
https://doi.org/10.70917/ijcisim-2026-3193
Article

SARS-2- CoV Variants and Therapuetic Responses

Towseef Ahmad Syed Bukhari[1], Ibtisam Nazir[2], Sameer Ahamad Sheikh[3], Aqib Rashid[4*], Lakshay Mangla[5], Farhat Jan[6], Asim Ashraf[7]

[1] Medical Laboratory Sciences KC Group of Institues Nawanshar Punjab.
[2] Dialysis Therapy Technology Rayat Bhara university Mohali Punjab.
Email: syedtawa525@gmail.com
[3] Dialysis Therapy Technology Rayat Bhara university Mohali Punjab.
[4*] School of Allied Health Science (SAH) CGC University Mohali Punjab.
Email: aqib.j4172@cgcuniversity.in
[5] Dr OM Prakesh Eye Institute Amritsar Punjab.
[6]Radiology and Imaging Technology Rayat Bhara university Mohali Punjab.
[7]Operation Theatre and Anesthesia Technology Rayat Bhara university Mohali Punjab.

Abstract: Background: The continued circulation and adaptive evolution of SARS-CoV-2 represents one of the most formidable challenges in contemporary infectious disease medicine. The virus has been demonstrated as a remarkable capacity for generating consecutive waves of variants that outdo immune defences and reduce the effectiveness of previously established therapeutic procedures Objective: The current evidence on variant-specific genetic changes, their phenotypic consequences, and their corresponding evolution of pharmacological interventions from direct-acting antivirals to host-directed immunomodulatory and next-generation broadly neutralizing antibodies. Methods: A systematic review was conducted, WHO epidemiological bulletins, and clinical trial registries was conducted. Studies addressing VOC genomics, clinical outcomes, therapeutic efficacy, and public health implications were included. Results: Five major VOCs Alpha, Beta, Gamma, Delta, and Omicron—have each reshaped the pandemic landscape through distinct spike protein alterations, with Omicron's 30+ mutations conferring unprecedented immune evasion. Antiviral agents such as nirmatrelvir/ritonavir and remdesivir retain activity across most variants, while several monoclonal antibodies have lost neutralizing potency. Immunomodulatory regimens incorporating dexamethasone and IL-6 inhibitors remain the cornerstone of severe disease management. Conclusion: Addressing SARS-CoV-2 as an evolving endemic pathogen requires adaptive therapeutic frameworks, investment in pan-coronavirus drug targets, and global strategies to close equity gaps in access to diagnostics and treatment.

Keywords: SARS, COVID 19, Omicron Variant, ACE2, therapeutic efficacy.

1. INTRODUCTION

The emergence of coronavirus disease 2019 (COVID-19) as a global pandemic marked a watershed moment in the history of infectious diseases [1]. Caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel betacoronavirus with zoonotic origins, the disease swept across geographic and demographic boundaries with a speed and breadth that overwhelmed even the most prepared healthcare systems. What makes SARS-CoV-2 particularly challenging is not merely its initial transmissibility or lethality, but its extraordinary capacity for genetic adaptation. Unlike many acute respiratory pathogens that dominate a season and recede, this virus has demonstrated a sustained evolutionary trajectory that has repeatedly altered the clinical and epidemiological calculus of the pandemic. SARS-CoV-2 belongs to the order Nidovirales, family Coronaviridae, and is classified within the betacoronavirus genus the same genus responsible for the 2003 SARS epidemic and the 2012 MERS outbreak. As a positive-sense, single-stranded RNA virus with a genome of approximately 29,891 nucleotides encoding 9,860 amino acids, it encodes structural proteins including Spike (S), Membrane (M), Envelope (E), and Nucleocapsid (N), alongside 16 non-structural proteins (nsps) that orchestrate viral replication.



The Spike protein, projecting from the virion surface to create the characteristic 'crown' appearance, is the primary mediator of host cell entry and the principal antigen for both natural immunity and vaccine-elicited immune responses. The spike protein's receptor-binding domain (RBD) docks onto the host angiotensin-converting enzyme 2 (ACE2) receptor, with subsequent priming by the transmembrane serine protease TMPRSS2 facilitating membrane fusion and viral internalization. It is within this very domain—and in the N-terminal domain (NTD) flanking it—that most clinically significant mutations have accumulated, conferring advantages in receptor affinity, transmissibility, and immune evasion. Understanding the precise molecular consequences of these mutations is therefore central to any effort aimed at developing durable therapeutics. The pandemic's trajectory shifted materially in late 2020 when genomic surveillance programs detected lineages with distinctive mutational profiles not seen in the ancestral Wuhan strain. The World Health Organization (WHO) and the Centres for Disease Control and Prevention (CDC) established formal classification frameworks distinguishing Variants of Concern (VOCs)—those with demonstrated epidemiological impact—from Variants of Interest (VOIs) with emerging signals. As of the end of 2021, five lineages had attained VOC designation: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529). Each of these has reshaped the pandemic in distinct ways, demanding continuous recalibration of public health measures and therapeutic protocols.

This review aims to provide an integrated, human-cantered analysis of how SARS-CoV-2 variants have driven—and in some cases outpaced—therapeutic innovation. Rather than cataloguing mutations in isolation, we examine their phenotypic and clinical consequences alongside the pharmacological tools developed to counter them. We draw attention to the evolving principle that a static therapeutic approach is fundamentally mismatched to a dynamically evolving pathogen, and that the pandemic's next chapter whatever form it takes will require adaptive, variant-proof strategies.

2. STRUCTURAL BIOLOGY AND MOLECULAR BASIS OF VIRAL ENTRY

To appreciate why certain mutations, carry such outsized consequences, it is instructive to first understand the entry mechanism of SARS-CoV-2 at the molecular level. The Spike glycoprotein exists as a homotrimer on the virion surface and is cleaved by host furin proteases at the S1/S2 boundary during viral maturation—a feature absents in SARS-CoV-1 that contributes to enhanced infectivity. The S1 subunit carries both the NTD and RBD, while the S2 subunit contains the fusion machinery. Upon RBD binding to ACE2, a conformational change exposes the S2 fusion peptide, which inserts into the host cell membrane to enable membrane fusion and viral genome delivery.



ACE2 receptor expression is not confined to the respiratory epithelium. It is distributed across multiple organ systems, including cardiomyocytes, renal proximal tubular cells, enterocytes of the ileum, urothelial cells, and neuronal tissues, which explains the multisystem nature of COVID-19. This distribution also implies that genetic variation in regions mediating ACE2 engagement—particularly mutations at positions 417, 484, and 501 within the RBD—can have effects that extend far beyond respiratory pathology. Mutations at these residues are recurrently observed across multiple VOCs and VOIs, reflecting strong positive selection pressure at the virus-host interface.



Fig. 1: SARS-CoV-2 Entry Pathway into Host Cells

3. SARS-COV-2 VARIANTS OF CONCERN (VOCS)

The emergence of Variants of Concern represents the evolutionary response of SARS-CoV-2 to the selective pressures of immunity—both vaccine-derived and natural—and to the diverse biological environments encountered in a globally mobile human population. Each VOC can be understood as a natural experiment in adaptive evolution:

the mutations that prevail are those conferring a fitness advantage within the immunological and epidemiological context in which they arise. Table 1 below provides a comparative overview of all five designated VOCs.

Table 1: Comparative Summary of SARS-CoV-2 Variants of Concern (VOCs). mAb = monoclonal antibody.

Variant (Lineage)	Geographic Origin	Key Spike Mutations	Phenotypic Consequences	Transmissibility	Immune Escape
Alpha (B.1.1.7)	United Kingdom (Dec 2020)	ΔH69/V70, ΔY144, N501Y, A570D, P681H, D1118H	Enhanced ACE2 binding; higher disease severity	44–81% higher than ancestral	Moderate
Beta (B.1.351)	South Africa (Oct 2020)	K417N, E484K, N501Y, D614G, A701V	Partial evasion of neutralizing antibodies; reduced mAb efficacy	Moderately increased	High
Gamma (P.1)	Brazil (Dec 2020)	L18F, K417T, E484K, N501Y, H655Y	Reduced neutralization by convalescent sera and vaccine antibodies	Moderate increase	High
Delta (B.1.617.2)	India (Dec 2020)	L452R, T478K, D614G, P681R, D950N	Highest ACE2 binding affinity; responsible for deadly 2nd wave	~96% more than ancestral	Moderate-High
Omicron (B.1.1.529)	South Africa (Nov 2021)	30+ spike mutations incl. K417N, E484A, N501Y, Q493R, G496S, Q498R	Unprecedented immune evasion; reduced severity per infection but higher overall case load	~2.8× more than Delta	Very High

Alpha Variant (B.1.1.7)

Identified through routine genomic surveillance in south eastern England in September 2020 and reported publicly in December, the Alpha variant (B.1.1.7) was the first to signal that SARS-CoV-2 could evolve beyond incremental drift. With 17 genomic mutations—8 in the spike protein—it established a template for VOC characterization. The N501Y substitution, located in the receptor-binding motif, enhances ACE2 affinity with measurable epidemiological consequences: Alpha was estimated to be 43–82% more transmissible than ancestral strains circulating at the same time. The P681H mutation, at the furin cleavage site, has since been implicated in enhanced cell entry efficiency. Of clinical note, retrospective matched cohort studies initially suggested comparable disease severity between B.1.1.7 and earlier lineages; however, subsequent analyses from multiple UK cohorts

demonstrated a modest but statistically significant increase in case fatality risk, estimated at approximately 61% higher relative mortality among hospitalized B.1.1.7 patients.

Beta Variant (B.1.351)

The Beta variant arose independently in the Eastern Cape of South Africa during the country's second wave in October 2020, accumulating nine spike mutations with particular clustering in the RBD. The triple RBD mutation constellation K417N/E484K/N501Y became the molecular signature of Beta, and each component carried immunological weight: E484K emerged as the most immunologically disruptive, substantially reducing antibody recognition. This was demonstrated across multiple platforms—convalescent plasma from previously infected individuals showed reduced neutralization, and several monoclonal antibody products became effectively inactivated against B.1.351. For vaccine manufacturers, Beta presented the first serious test of whether mRNA-based platforms could respond rapidly to antigenic shift—a question with lasting implications for variant-adaptive vaccine strategies.

Gamma Variant (P.1)

Originating in Manaus, Brazil—a city that had already experienced a devastating first wave thought to have achieved substantial herd immunity—the Gamma variant (P.1) brought with it the troubling concept of reinfection at a population scale. Sharing several key mutations with Beta (notably E484K and N501Y, plus its own K417T substitution), Gamma demonstrated that prior infection did not provide reliable protection against antigenically distinct lineages. The epidemiological implications were profound: if natural immunity from infection could be circumvented, vaccine-derived immunity based on the original Wuhan spike would face similar challenges. Gamma's spread to 45 countries by March 2021 elevated it to the status of VOC and underscored the inadequacy of nationally siloed pandemic responses.

Delta Variant (B.1.617.2)

If Alpha demonstrated enhanced transmissibility and Gamma raised the spectre of immune evasion, Delta synthesized both—and added a degree of virulence that made the April–May 2021 second wave in India one of the pandemic's most catastrophic episodes. The L452R and T478K RBD mutations in Delta confer the highest ACE2 binding affinity among the original four VOCs, increasing both viral entry efficiency and the viral load in infected individuals. Combined with P681R at the furin cleavage site (more potent than Alpha's P681H), Delta achieved a transmissibility approximately 97% higher than the ancestral strain. From a therapeutic standpoint, Delta represented the inflection point where several authorized monoclonal antibodies—particularly bamlanivimab/etesevimab—lost clinical utility, prompting regulatory revisions. This reinforced the need for therapeutics targeting conserved non-spike viral machinery.

Omicron Variant (B.1.1.529)

Omicron's detection in southern Africa in November 2021 was immediately recognized as a paradigm-shifting event. With over 30 mutations in the spike protein alone—more than the cumulative spike mutations of all previous VOCs combined—Omicron's mutational profile was qualitatively different from its predecessors. Of these, 15 mutations reside in the RBD, with several (Q493R, G496S, Q498R, Y505H) providing substantial resistance to antibodies generated by both vaccination and prior infection. The E484A substitution (analogous to E484K in Beta/Gamma) disrupts recognition by a major class of neutralizing antibodies. The N679K and P681H mutations optimize furin cleavage, enhancing cellular entry.

Omicron's initial epidemiological trajectory confirmed fears of unprecedented transmissibility—estimated 2.8 times more infectious than Delta—but subsequent clinical data from South Africa, the UK, and Denmark indicated attenuated intrinsic virulence per infection, particularly in vaccinated individuals. This apparent paradox (highly immune evasive yet less severe per case) may reflect receptor tropism shifts; Omicron replicates preferentially in bronchial epithelium rather than lung parenchyma, potentially explaining reduced alveolar disease. However, the sheer volume of Omicron infections globally overwhelmed healthcare capacity and produced more absolute severe cases than any prior variant, erasing the apparent severity advantage at the population level.

4. SARS-COV-2 VARIANTS OF INTEREST (VOIS)

Variants of Interest occupy an intermediate epidemiological space—characterized by genomic features of potential concern but without yet achieving the documented population-level impact that warrants VOC status. Their monitoring is nonetheless critical, as several VOIs have served as precursors to or co-evolutionary parallels of VOCs,

sharing key mutations that later proved clinically significant. Table 2 summarizes the WHO-designated VOIs and their defining features.

Table 2: WHO-Designated Variants of Interest (VOIs): Origins, Genomic Features, and Clinical Relevance.

Designation	Lineage	First Detected	Notable Mutations	Clinical Significance
Epsilon	B.1.427/B.1.429	USA, Jun 2020	L452R, D614G	18.6–24% increased transmissibility vs. wildtype
Zeta	P.2	Brazil, Apr 2020	E484K, L18F, D614G	Reduced mAb neutralization; epidemiologically displaced
Eta	B.1.525	West Africa/UK	E484K, Δ144, F888L	Shared mutations with Alpha and Beta variants
Iota	B.1.526	New York, Nov 2020	E484K, D253G	Associated with partial immune evasion in urban populations
Kappa	B.1.617.1	India, Dec 2020	L452R, E484Q, P681R	Precursor co-lineage to Delta; reduced severity compared to Delta
Lambda	C.37	Peru, Aug 2020	L452Q, F490S, D614G	Recognized VOI by WHO Jun 2021; limited global spread
Mu	B.1.621	Colombia, Jan 2021	R346K, E484K, N501Y	Resistant to convalescent and vaccine-elicited immunity in vitro

5. ETIOLOGY, TAXONOMY, AND GENOMIC ARCHITECTURE

Coronaviruses constitute a phylogenetically diverse family with four genera—Alpha coronavirus, Betacoronavirus, Gamma coronavirus, and Delta coronavirus—distinguished by genome structure and host tropism. Among human-infective coronaviruses, the alpha genus contributes HCoV-229E and HCoV-NL63 (typically mild respiratory illness), while the beta genus includes HCoV-OC43, HCoV-HKU1, MERS-CoV, SARS-CoV, and now SARS-CoV-2. The beta genus thus disproportionately accounts for the three major epidemic coronaviruses encountered in the 21st century.

The genome of SARS-CoV-2 spans 29,891 nucleotides organized into approximately 14 open reading frames (ORFs). ORF1a and ORF1b account for roughly two-thirds of the genome and encode the 16 non-structural

proteins (nsp1–16) that form the replication-transcription complex, including the RNA-dependent RNA polymerase (RdRp, nsp12), the helicase (nsp13), the 3'-to-5' exoribonuclease that confers proofreading capacity (nsp14), and the cap-modifying enzymes that help viral mRNA evade innate immune detection. The remaining third encodes structural proteins (S, E, M, N) and several accessory proteins with immunomodulatory roles. Notably, the proofreading function of nsp14 distinguishes coronaviruses from most other RNA viruses and limits their mutation rate—yet sufficient evolutionary pressure from billions of infections globally has generated remarkable diversity nonetheless.

6. EPIDEMIOLOGY

The epidemiological story of COVID-19 is one of cascading waves, each reshaped by viral evolution, waning immunity, and public health interventions. The initial outbreak, identified in Wuhan, Hubei Province, China in December 2019, achieved pandemic status by March 2020—the fastest documented progression from outbreak to

pandemic in WHO history. By late 2021, over 281 million confirmed cases and more than 5.4 million deaths had been reported, with wide acknowledgment that true excess mortality substantially exceeded reported figures due to under diagnosis and strained health systems.

The demographics of severe disease follow a clear pattern: older age and male sex are independent risk factors for progression to severe illness and death, likely reflecting both immunosenescence and differences in ACE2 expression and innate immune responsiveness. Comorbidities—diabetes, hypertension, obesity, cardiovascular disease, and immunosuppression—compound these risks multiplicatively. Socioeconomic vulnerability, driven by occupational exposure, housing density, and differential access to healthcare and therapeutics, has reinforced existing health disparities.

7. PATHOPHYSIOLOGY AND MULTI-ORGAN INVOLVEMENT

COVID-19's clinical phenotype ranges from entirely asymptomatic infection to rapidly progressive multi-organ failure, a range that reflects the interplay between viral tropism, host immune response, and individual comorbid burden. The primary route of infection remains respiratory—SARS-CoV-2 establishes initial replication in the upper airways, with subsequent spread to the lower respiratory tract in a subset of patients. In severe cases, alveolar infection triggers an inflammatory cascade that can culminate in diffuse alveolar damage (DAD), cytokine release syndrome (CRS), and acute respiratory distress syndrome (ARDS).

What distinguishes COVID-19 from many prior respiratory pandemics is the frequency and diversity of extra pulmonary manifestations. The near-universal expression of ACE2 across organ systems creates multiple potential sites of direct viral cytotoxicity, and systemic immune activation generates indirect organ injury even in the absence of detectable viral replication at affected sites. Below, we address the most clinically significant organ-specific manifestations.

Pulmonary Pathology

Histopathological examination of autopsy specimens has established diffuse alveolar damage as the dominant pulmonary finding, present in up to 87% of COVID-19 fatalities. Features include type II pneumocystis hyperplasia, hyaline membrane formation, and intra-alveolar fibrin deposition. Of particular note is the distinctive vascular pathology: pulmonary microvascular thrombosis (fibrin and platelet micro thrombi found in 84% of autopsy cases), large vessel pulmonary emboli in approximately 42% of cases, and endothelialitis—suggesting that COVID-19 pulmonary disease is not merely pneumonia but a vascular inflammatory syndrome with respiratory manifestation.

Cardiovascular Effects

Cardiac involvement in COVID-19 is multifactorial and encompasses myocarditis (both direct ACE2-mediated viral cytotoxicity and immune-mediated inflammation), arrhythmias driven by cytokine-induced electrophysiological remodelling, pericarditis, and stress cardiomyopathy. The SARS-CoV-2 genome has been detected in myocardial tissue in autopsy series, though the clinical significance of low-level cardiac viral RNA in the absence of active replication remains debated. Proinflammatory cytokines—particularly IL-6 and TNF-α—mediate systemic vascular inflammation that contributes to both myocardial injury and the pronounced coagulopathy characteristic of severe COVID-19.

Neurological Manifestations

Neurological involvement spans a wide spectrum from anosmia and fatigue (highly prevalent in mild disease) to encephalopathy, stroke, and post-acute sequelae (Long COVID). ACE2 receptors have been identified in both human and murine brain tissue, and SARS-CoV-2 neuroinvasion may occur via multiple routes: trans synaptic transfer through the olfactory nerve, hematogenous spread, or migration of infected leukocytes across a compromised blood-brain barrier. Autopsy studies reveal widespread hypoxic-ischemic injury in cerebral and cerebellar tissues, while neuroinflammatory and direct viral encephalitic changes appear less common—suggesting that cerebrovascular rather than direct viral mechanisms dominate.

Gastrointestinal, Hepatic, and Renal Manifestations

The gastrointestinal tract expresses high levels of ACE2 in enterocytes, and faecal viral RNA shedding—often persisting beyond respiratory clearance—supports direct enteric involvement. Endoscopic specimens demonstrate viral Nucleocapsid protein staining in gastric, duodenal, and rectal epithelium, alongside lamina propria inflammation. Liver injury is common (30–50% of hospitalized patients show transaminase elevation) and likely multifactorial:

direct ACE2-mediated hepatocyte injury, hepatic ischemia, drug-induced liver injury from antivirals or antibiotics, and immune-mediated hepatitis all contribute. Renal involvement, manifesting as acute kidney injury (AKI) in 20–40% of ICU patients, involves direct proximal tubular injury, renin-angiotensin-aldosterone system disruption, and sepsis-related hypo perfusion.

8. DIAGNOSTIC EVALUATION

Accurate and timely diagnosis forms the indispensable foundation of effective COVID-19 management. The choice of diagnostic modality must be calibrated to clinical context, available resources, and—increasingly—the need for variant surveillance. Table 3 outlines the diagnostic framework.

Table 3: Diagnostic Workup Framework for Suspected SARS-CoV-2 Infection. RT-PCR = Reverse Transcriptase Polymerase Chain Reaction; RADT = Rapid Antigen Detection Test; WGS = Whole Genome Sequencing.

DIAGNOSTIC WORKUP	SPECIMEN / TEST DETAILS
Primary Test: RT-PCR (Gold Standard)	**Specimen:** Nasopharyngeal/oropharyngeal swab
Sensitivity: Depends on timing, collection, and viral load	**Specificity:** ~100% for approved FDA commercial assays
Antigen Rapid Test (RADT)	Faster turnaround; lower sensitivity than PCR; use when PCR unavailable
Chest CT / X-Ray	Bilateral ground-glass opacities; used when PCR negative but clinical suspicion high
Lab Panel: CBC, CMP, CRP, D-dimer, Ferritin, LDH, Procalcitonin	Prognostic value; elevated D-dimer and ferritin associated with severe disease
Genomic Sequencing (WGS / Nanopore)	Variant identification and surveillance; not for routine clinical diagnosis

Molecular Testing

Real-time reverse transcriptase polymerase chain reaction (RT-PCR) targeting conserved genomic regions (typically RdRp, N gene, or E gene) remains the gold standard for SARS-CoV-2 diagnosis. Its near-perfect specificity (approaching 100% for commercial FDA-approved assays without cross-contamination) makes it the definitive test for clinical and medico-legal purposes. Sensitivity varies from 60% to 98% depending on specimen type (nasopharyngeal > saliva > nasal swab), timing relative to exposure (optimal 3–7 days' post-exposure), and technical execution. Crucially, as dominant variants shift, routine surveillance RT-PCR must be paired with genomic sequencing programs to detect variant drift—a lesson underscored by the rapid emergence of Omicron from regions with high sequencing capacity.

Serological and Antigen Testing

Rapid antigen detection tests (RADTs) targeting the Nucleocapsid protein offer turnaround times of 15–30 minutes at the cost of sensitivity (typically 60–80% against symptomatic infection, substantially lower in asymptomatic cases and for Omicron). They are most valuable in point-of-care settings, mass screening, and resource-limited environments. Serological assays detecting anti-spike or anti-nucleocapsid IgG/IgM play a role in seroprevalence studies and assessment of prior exposure but have limited utility in acute diagnosis given the 1–2 week lag in seroconversion.

9. THERAPEUTIC LANDSCAPE

The therapeutic response to COVID-19 has followed an unusual trajectory—beginning with emergency repurposing of drugs with theoretical mechanisms, proceeding through a phase of rigorous randomized trial-driven evidence generation, and culminating in a portfolio of approved and authorized agents that reflect both the virology of SARS-CoV-2 and the immunopathology of severe disease. What is perhaps most instructive about this evolution is the rate at which drugs once championed (hydroxychloroquine, lopinavir/ritonavir) were rigorously disproven, while others (dexamethasone, tocilizumab) were elevated to standard of care through landmark trials. The framework for

COVID-19 treatment is now organized around the two phases of illness: an early viral phase amenable to antiviral intervention, and a late inflammatory phase requiring immunomodulatory approaches.

Antiviral Agents

Table 4: Antiviral Agents in COVID-19 Management: Mechanisms, Evidence Base, and Variant Activity. RCT = Randomized Controlled Trial; EUA = Emergency Use Authorization; SOC = Standard of Care; Mpro = Main Protease; RdRp = RNA-dependent RNA Polymerase.

Drug	Class	Mechanism	Clinical Evidence	Variant Activity	Status
Nirmatrelvir/ Ritonavir (Paxlovid)	Protease Inhibitor + PK Booster	Inhibits Mpro; ritonavir boosts plasma levels	89% reduction in hospitalization/ death (within 3 days of onset)	Broadly active; conserved Mpro target across variants	EUA/Approved
Remdesivir	Nucleoside Analog	Inhibits viral RNA-dependent RNA polymerase (RdRp)	Shortened time to recovery; benefit in mild-moderate hospitalized patients	Active against ancestral + variants; less benefit in Omicron era	FDA Approved
Molnupiravir	Nucleoside Analog	Mutagenic incorporation into viral RNA via RdRp	~30% reduction in hospitalization (Phase 2/3)	Broad-spectrum; active in mild COVID-19	EUA
Sotrovimab	Monoclonal Antibody	Neutralizes conserved spike epitope shared with SARS-CoV-1	Active against Alpha, Beta, Gamma, Delta in vitro	Reduced activity vs. BA.2/BA.4/ BA.5 Omicron subvariants	EUA (limited use)
Lopinavir/Ritonavir	HIV Protease Inhibitors	Repurposed; disrupts viral protease processing	No clinical benefit in hospitalized severe COVID-19 (RCT)	No advantage over SOC in trials	Discontinued for COVID-19
Hydroxychloroquine	Antimalarial	Interferes with endosomal acidificat	No mortality benefit; multiple large RCTs negative	Not active in clinical setting	Not Recommended

		ion and viral entry		despite in vitro data	
Ivermectin	Antiparasitic	Nuclear import inhibition of importin α/β (in vitro)	Insufficient evidence from RCTs; in vitro concentrations not clinically achievable	No validated clinical benefit	Not Recommended

Nirmatrelvir/ritonavir (Paxlovid) represents the most significant advance in outpatient COVID-19 treatment since the pandemic began. Nirmatrelvir targets the SARS-CoV-2 main protease (Mpro/3CLpro)—a highly conserved enzyme with no human homolog, making it an ideal drug target—while ritonavir acts as a pharmacokinetic booster by inhibiting cytochrome P450 3A4 to maintain therapeutic nirmatrelvir plasma concentrations. The interim EPIC-HR trial data showed 89% reduction in hospitalization or death when treatment was initiated within three days of symptom onset in high-risk unvaccinated adults—an effect size remarkable in the context of COVID-19 therapeutics. Critically, the Mpro is structurally conserved across variants, and nirmatrelvir has retained activity against Omicron and its sub lineages, making it the most robust variant-agnostic oral antiviral currently available.

Remdesivir, a broad-spectrum nucleoside analogue prodrug that incorporates into viral RNA and induces delayed chain termination at the RdRp, became the first FDA-approved antiviral for COVID-19 based on the ACTT-1 trial showing shortened time to recovery in hospitalized patients. Its role has been refined over time: it is most beneficial in patients with moderate disease who are early in their clinical course; in mechanically ventilated patients, benefit is less consistent. The advent of more transmissible Omicron variants—which may replicate faster and overwhelm antiviral action—has somewhat attenuated remdesivir population-level impact, but it remains integral in moderate inpatient care protocols.

Two repurposed drugs that generated substantial early controversy—hydroxychloroquine and lopinavir/ritonavir—have been conclusively withdrawn from COVID-19 treatment guidelines following multiple large randomized trials, including the UK RECOVERY trial (hydroxychloroquine) and a randomized study in severe COVID-19 (lopinavir/ritonavir). Their removal from clinical use is instructive: in vitro activity against SARS-CoV-2 proved non-translatable to clinical benefit, and the harm of exposing patients to adverse effects without evidence of efficacy could not be justified.

Immunomodulatory Agents

Table 5: Immunomodulatory Agents in COVID-19 Management: Mechanisms, Evidence, and Clinical Indications. IL-6R = Interleukin-6 Receptor; JAK = Janus Kinase; STAT = Signal Transducer and Activator of Transcription; ISG = Interferon-Stimulated Genes; RCT = Randomized Controlled Trial.

Agent	Drug Class	Mechanism of Action	Clinical Evidence	Indication
Dexamethasone	Corticosteroid	Suppresses cytokine storm; inhibits NF-κB and inflammatory transcription	**RECOVERY trial:** 35% mortality reduction in ventilated patients	Severe/Critical COVID-19 on oxygen/ventilation
Tocilizumab	Anti-IL-6R mAb	Blocks IL-6 receptor; attenuates hyperinflammatory cytokine cascade	**RECOVERY + REMAP-CAP:** reduced 28-day mortality in ICU patients when	Critical COVID-19 with elevated inflammatory markers

			combined with steroids	
Baricitinib	JAK1/2 Inhibitor	Inhibits JAK-STAT signaling pathway; dual antiviral + anti-inflammatory	**ACTT-2:** shortened recovery time; FDA approved in combination with remdesivir	Hospitalized adults requiring supplemental oxygen
Anakinra	IL-1Ra	Competitively inhibits IL-1β receptor; downregulates fever and systemic inflammation	Small case-control studies suggest benefit in hyperinflammatory COVID-19; RCT data limited	Investigational; cytokine storm with macrophage activation features
Inhaled IFN-β-1a	Interferon	Restores innate antiviral state suppressed by SARS-CoV-2; upregulates ISGs	SNG001 trial: improved clinical recovery vs. placebo in randomized Phase 2	Moderate COVID-19; early phase intervention

The immunomodulatory revolution in COVID-19 care was initiated by the RECOVERY trial's demonstration that dexamethasone 6 mg daily for 10 days reduced 28-day mortality by 35% in mechanically ventilated patients—arguably the single most impactful therapeutic discovery of the pandemic. This finding validated the hypothesis that the late hyper inflammatory phase of COVID-19 is driven by dysregulated host immunity rather than unchecked viral replication, and that suppressing this response with corticosteroids produces net clinical benefit in severe disease. The caveat—and it is an important one—is that dexamethasone may be harmful if given during the early viral phase before immunopathology dominates, an observation that speaks to the importance of phase-appropriate therapy.

IL-6 pathway inhibition via tocilizumab (an anti-IL-6 receptor monoclonal antibody) has been validated as an additive strategy to corticosteroids in critically ill COVID-19 patients. The RECOVERY and REMAP-CAP collaborative trials demonstrated that tocilizumab, when added to dexamethasone in patients with rapidly increasing oxygen requirements and elevated CRP (≥75 mg/L), further reduced 28-day mortality. Baricitinib, a JAK1/2 inhibitor with dual antiviral and anti-inflammatory properties, has also demonstrated survival benefit in combination with remdesivir, offering a small-molecule alternative to biologic immunomodulation.

10. SEVERITY-BASED CLINICAL MANAGEMENT ALGORITHM

Rational COVID-19 management requires stratification by clinical severity at presentation and dynamic reassessment as the disease evolves. The NIH COVID-19 Treatment Guidelines provide the most frequently updated evidence-based framework, informed by global trial data and real-world safety surveillance. Table 6 presents a severity-stratified management guide synthesized from current evidence.

Table 6: Severity-Stratified COVID-19 Management Algorithm. SpO2 = Peripheral Oxygen Saturation; ARDS = Acute Respiratory Distress Syndrome; NIV = Non-Invasive Ventilation; ECMO = Extracorporeal Membrane Oxygenation; PPE = Personal Protective Equipment; IBW = Ideal Body Weight.

Severity Category	**Clinical Criteria**	**Recommended Interventions**	**Setting & Monitoring**
Asymptomatic / Pre-symptomatic	RT-PCR positive; no symptoms	Isolation (≥5 days); symptom monitoring; no pharmacotherapy needed unless high-risk profile	Home; daily self-assessment

Mild	Fever, cough, fatigue; SpO2 ≥95%; no dyspnea	Supportive care; antipyretics; hydration; nirmatrelvir/ritonavir for high-risk patients within 5 days	Ambulatory; telehealth follow-up; return if SpO2 drops
Moderate	SpO2 93–94%; pneumonia on imaging; tachypnea	Supplemental O2 to maintain SpO2 ≥95%; remdesivir (5 days); dexamethasone if requiring O2; anticoagulation prophylaxis	Inpatient; continuous pulse oximetry; CBC/CRP/D-dimer daily
Severe	SpO2 <93% on room air; RR >30; bilateral infiltrates >50%	High-flow O2/NIV; dexamethasone 6mg for 10 days; tocilizumab/baricitinib; therapeutic anticoagulation if indicated; remdesivir	ICU step-down; hemodynamic monitoring; prone positioning if refractory hypoxemia
Critical	Mechanical ventilation; ARDS; multi-organ failure; septic shock	Lung-protective ventilation (Vt 6ml/kg IBW); prone ≥16 hrs/day; empiric antibiotics if bacterial co-infection suspected; ECMO if refractory	ICU; full PPE (N95, gown, gloves, face shield); aerosolization precautions

FIGURE 2: Clinical Decision Pathway for COVID-19 Patient Management



Figure 2: Stepwise clinical management algorithm for COVID-19 based on disease severity at presentation and trajectory. Therapy should be reassessed at each clinical decision point.

11. DISCUSSION

Surveying the full arc of SARS-CoV-2's evolution alongside the therapeutic responses it has provoked, several themes emerge that deserve explicit articulation—not just as observations about the past pandemic, but as principles for future preparedness.

First, the concept of variant-driven therapeutic obsolescence is now empirically established. The progression from Alpha to Omicron has rendered multiple once-effective monoclonal antibodies (bamlanivimab, casirivimab/imdevimab, and partially sotrovimab against later Omicron sub variants) clinically inactive—a cautionary example of biological drug development without adequate variant-proofing built into the antibody design pipeline. Broadly neutralizing antibodies (bnAbs) targeting conserved epitopes in the stem helix, S2 subunit, or cross-reactive RBD sites represent the conceptually sound next generation, but translating these academic discoveries into therapeutics at scale remains an unmet challenge.

Second, the success of non-spike-targeting small molecule antivirals—particularly nirmatrelvir against Mpro—validates the strategy of identifying essential, structurally conserved viral enzymes as drug targets. The same logic applies to the RdRp targeted by remdesivir and molnupiravir. These enzymes are under stronger conservation pressure than the exposed, antibody-targeted spike surface, and their inhibition is less susceptible to single-mutation resistance. Combination antiviral regimens, analogous to HAART in HIV, should be prioritized in clinical research to prevent the emergence of resistance to any single agent.

Third, the pandemic has illuminated with uncomfortable clarity the gap between what is therapeutically possible and what is equitably accessible. Paxlovid and other effective antivirals require a functional primary care infrastructure for identification of high-risk individuals within the narrow treatment window. In low- and middle-income countries where this infrastructure is least developed, these drugs have had the least impact—despite representing the populations bearing a disproportionate burden of COVID-19 mortality. Closing this gap requires not just manufacturing scale-up and pricing agreements, but investment in diagnostic capacity and healthcare worker training that makes early identification and treatment feasible.

Finally, SARS-CoV-2 is perhaps best understood now not as an acute pandemic pathogen but as a permanent fixture of the human virome—evolving, endemic, but substantially more manageable than in 2020 through a combination of population immunity and a therapeutic arsenal unimaginable at the outset. The challenge is to maintain that arsenal's relevance through adaptive regulatory frameworks, real-time genomic surveillance, and a global commitment to the principle that pandemic preparedness is a public good, not a commodity.

12. CONCLUSIONS

SARS-CoV-2 has provided an unprecedented real-world study in the co-evolution of a pathogen and the human response to it. Its five VOCs—Alpha through Omicron—have each redefined what transmissibility and immune evasion look like in practice, demanding continuous recalibration of vaccines, therapeutics, and clinical protocols. The major lessons of this review are clear: spike-targeted therapies are inherently vulnerable to mutational escape; conserved targets (Mpro, RdRp) offer more durable drug development opportunities; immunomodulatory regimens anchored in dexamethasone and IL-6 inhibition have demonstrably reduced mortality; and access to these interventions remains deeply inequitable.

Going forward, variant-proof therapeutics—defined by their activity against conserved viral machinery rather than antigenically labile surface proteins—and global equity in their deployment must become the dual pillars of an endemic-phase SARS-CoV-2 strategy. The science has advanced with remarkable speed; the imperative now is to ensure that this science reaches every patient who needs it.

References

1. Galloway SE, Paul P, MacCannell DR, et al. Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States, December 29, 2020–January 12, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(3):95-99.
2. Volz E, Mishra S, Chand M, et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature. 2021;593(7858):266-269.
3. Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372(6538):eabg3055.
4. Tegally H, Wilkinson E, Giovanetti M, et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021;592(7854):438-443.
5. Faria NR, Mellan TA, Whittaker C, et al. Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil. Science. 2021;372(6544):815-821.
6. Vaughan A. Omicron emerges. New Sci. 2021;252(3363):7.

7. Gu H, Krishnan P, Ng DYM, et al. Probable Transmission of SARS-CoV-2 Omicron Variant in Quarantine Hotel, Hong Kong, China, 2021. Emerg Infect Dis. 2022;28(2):460-462.
8. Chen J, Wang R, Gilby NB, Wei GW. Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance. J Chem Inf Model. 2022;62(2):412-422.
9. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-280.
10. Walls AC, Park YJ, Tortorici MA, et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181(2):281-292.
11. Mahase E. Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ. 2021;375:n2713.
12. Singh AK, Singh A, Singh R, Misra A. Molnupiravir in COVID-19: A systematic review of literature. Diabetes Metab Syndr. 2021;15(6):102329.
13. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 — Final Report. N Engl J Med. 2020;383(19):1813-1826.
14. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693-704.
15. REMAP-CAP Investigators. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021;384(16):1491-1502.
16. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol. 2020;215:108427.
17. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
18. Patel KP, Patel PA, Vunnam RR, et al. Gastrointestinal, hepatobiliary, and pancreatic manifestations of COVID-19. J Clin Virol. 2020;128:104386.
19. Gabarre P, Dumas G, Dupont T, et al. Acute kidney injury in critically ill patients with COVID-19. Intensive Care Med. 2020;46(7):1339-1348.
20. Borczuk AC, Salvatore SP, Seshan SV, et al. COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City. Mod Pathol. 2020;33(11):2156-2168.
21. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;382(19):1787-1799.
22. Monk PD, Marsden RJ, Tear VJ, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(2):196-206.
23. Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). Crit Care Med. 2020;48(6):e440-e469.
24. Gebhard C, Regitz-Zagrosek V, Neuhauser HK, et al. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ. 2020;11(1):29.
25. Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;324(8):782-793.